Unibest 优贝德

APIs Recommended for You

Three inputs drive the ranking: the region of your target market, the indication classes you follow, and each molecule's patent-expiry window. Every card states why it was picked.

What drives these picks

Region
全球

按通用需求排序,可自行切换目标市场

Indications you follow
Oncology / Hematology
Visitor region (by IP)
全球fallback

未识别到访客区域,展示全量热门品种;选定目标国后可查看对应注册路径

No direction yet? This page picks from our catalogue. To answer what a market will need next, use the demand-chain board and work down from economy, demography and diet.

Demand-chain board →

Which therapeutic areas do you follow?

Multi-select, change any time

Sign in and we remember your market and interests — you land straight on this page next time.

Oncology / HematologyOff-patent · 2026 (indicative)
Ruxolitinib

Myelofibrosis and polycythemia vera; topical formulations for vitiligo and atopic dermatitis

Why it was picked
  • · 你关注的适应症:肿瘤 / 血液(+35)
  • · 已到期(+25)
  • · 已商业化可供(+10)
  • · GMP / DMF 就绪(+4)
Oncology / HematologyTo be assessed3 intermediates
Apalutamide

Non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer

Why it was picked
  • · 你关注的适应症:肿瘤 / 血液(+35)
  • · 待评估(+2)
  • · 已商业化可供(+10)
  • · 已收录关键中间体,可沿供应链往下采购(+15)
  • · GMP / DMF 就绪(+4)
Oncology / HematologyTo be assessed
Afuresertib

Targeted therapy of multiple myeloma and various solid tumors

Why it was picked
  • · 你关注的适应症:肿瘤 / 血液(+35)
  • · 待评估(+2)
  • · 已商业化可供(+10)
  • · GMP / DMF 就绪(+4)
Oncology / HematologyTo be assessed
Berzosertib

Advanced solid tumors (ovarian, NSCLC, etc.) with chemo/radiation sensitization

Why it was picked
  • · 你关注的适应症:肿瘤 / 血液(+35)
  • · 待评估(+2)
  • · 已商业化可供(+10)
  • · GMP / DMF 就绪(+4)
Oncology / HematologyTo be assessed
Eltanexor

Myelodysplastic syndromes (MDS) and acute myeloid leukemia

Why it was picked
  • · 你关注的适应症:肿瘤 / 血液(+35)
  • · 待评估(+2)
  • · 已商业化可供(+10)
  • · GMP / DMF 就绪(+4)
Oncology / HematologyTo be assessed
Itacitinib

Graft-versus-host disease (GVHD) and related hematologic malignancies

Why it was picked
  • · 你关注的适应症:肿瘤 / 血液(+35)
  • · 待评估(+2)
  • · 已商业化可供(+10)
  • · GMP / DMF 就绪(+4)
Oncology / HematologyTo be assessed
Vactosertib

Solid tumors and myelodysplastic syndromes; fibrosis indications in research

Why it was picked
  • · 你关注的适应症:肿瘤 / 血液(+35)
  • · 待评估(+2)
  • · 已商业化可供(+10)
  • · GMP / DMF 就绪(+4)
Oncology / HematologyTo be assessed
Vistusertib

Advanced solid tumors with PI3K/mTOR pathway aberrations

Why it was picked
  • · 你关注的适应症:肿瘤 / 血液(+35)
  • · 待评估(+2)
  • · 已商业化可供(+10)
  • · GMP / DMF 就绪(+4)
Oncology / HematologyTo be assessed
Vociprotafib

Targeted therapy of solid tumors carrying MAPK-pathway aberrations

Why it was picked
  • · 你关注的适应症:肿瘤 / 血液(+35)
  • · 待评估(+2)
  • · 已商业化可供(+10)
  • · GMP / DMF 就绪(+4)
Oncology / HematologyTo be assessed
Ensartinib

First- and later-line treatment of ALK-positive non-small cell lung cancer

Why it was picked
  • · 你关注的适应症:肿瘤 / 血液(+35)
  • · 待评估(+2)
  • · 已商业化可供(+10)
Anti-infectivesOff-patent · 2026 (indicative)4 intermediates
Letermovir

Prophylaxis of cytomegalovirus (CMV) infection in adult recipients of allogeneic hematopoietic stem cell transplant

Why it was picked
  • · 全球需求旺盛类目(+30)
  • · 已到期(+25)
  • · 已商业化可供(+10)
  • · 已收录关键中间体,可沿供应链往下采购(+15)
  • · GMP / DMF 就绪(+4)
Metabolic / EndocrineOff-patent · 2026 (indicative)3 intermediates
Semaglutide

Glycemic control in type 2 diabetes and weight management; reduces cardiovascular risk

Why it was picked
  • · 全球需求旺盛类目(+30)
  • · 已到期(+25)
  • · 已商业化可供(+10)
  • · 已收录关键中间体,可沿供应链往下采购(+15)
  • · GMP / DMF 就绪(+4)

Patent expiry compiled from public sources and indicative only; defer to national patent offices and the Orange Book.